Last reviewed · How we verify
Oxycodone hydrochloride tablet 15 mg
At a glance
| Generic name | Oxycodone hydrochloride tablet 15 mg |
|---|---|
| Also known as | immediate-release oxycodone |
| Sponsor | Mallinckrodt |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study) (PHASE4)
- Opioid & Steroid Use Following Tonsillectomy in Pediatric Patients (PHASE4)
- Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints (EARLY_PHASE1)
- Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) (PHASE1)
- Pain Control After Lumbar Spine Fusion (PHASE4)
- Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation (PHASE1)
- Are Opioids Needed After ACL Reconstruction (PHASE4)
- Novel Multimodal Pain Control Protocol for Minimally Invasive Gynecologic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxycodone hydrochloride tablet 15 mg CI brief — competitive landscape report
- Oxycodone hydrochloride tablet 15 mg updates RSS · CI watch RSS
- Mallinckrodt portfolio CI